Biotech investments

NUCLIDIUM 84 million euros for radiopharmaceuticals

84 million euros for NUCLIDIUM. Copper-based radiopharmaceuticals receive strong funding.
News by Marc Nemitz Marc Nemitz · München, 10. July 2025

The biotech NUCLIDIUM AG has closed a Series B financing round of 84 million euros. The round was led by a broad consortium of international investors, including Bayern Kapital, Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners and other renowned investors.

Focus on copper-based radiotheranostics

NUCLIDIUM develops copper-based radiopharmaceuticals for the targeted diagnosis and treatment of tumors. The company's platform uses the isotopes copper-61 for imaging and copper-67 for therapeutic applications. Initial clinical data indicate improved imaging for metastatic prostate cancer, neuroendocrine tumors and breast cancer.

We are now entering the next clinical phases with our first compounds for the diagnosis and treatment of metastatic prostate cancer, neuroendocrine tumors and breast cancer.

Dr. Leila Jaafar, CEO and co-founder of NUCLIDIUM AG

Funds for clinical development and production expansion

The fresh capital will be used to expand the clinical pipeline and build up global production capacities. At the same time, NUCLIDIUM intends to expand strategic partnerships with clinics and research institutions, particularly in Europe and North America.

Investors focus on scalable solution

Not only is the data from the first clinical trials of NUCLIDIUM's active ingredients promising, the company also has an experienced, interdisciplinary team with extensive technical expertise.

Monika Steger, Managing Director of Bayern Kapital

In addition to clinical progress, the company impressed with its proprietary, scalable manufacturing process. This is intended to address challenges in radiopharmacy, such as security of supply and sustainability. Bayern Kapital sees NUCLIDIUM as a promising investment in the growing precision oncology market.


Like it? Please spread the word:


Newsletter

Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.

LinkedIn Connect

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen

Similar posts